Incidence of prostate cancer is on the rise

Approximately 10 to 20 percent of men with prostate cancer present with metastatic disease, and in many others metastases develop despite treatment with surgery or radiotherapy.

Progression to androgen-independent prostate cancer takes 5-7 years and is characterized by biochemical or diagnostic changes, despite testosteronemia levels similar to those after castration. The presentation of hormone refractory prostate cancer (HRCP) is rising with the increasing incidence of prostate cancer coupled with a prognosis of greater life expectancy.